ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024
GlobeNewswire
· *Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) *
·..
· *Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) *
·..
BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing..
· *Further expansion of management expertise to accelerate BellaSeno´s market entry*
*Leipzig, Germany, April 3, 2024*..